Episode Details
Back to Episodes
Haemonetics Stock Slumps Amid Growth Woes | Business and Finance News
Published 2 days, 8 hours ago
Description
Haemonetics stock is sliding, down 7.2% in six months while the S&P 500 climbs — and for good reason: sluggish organic growth, tiny scale in a big industry, and underwhelming returns on capital make it hard to justify chasing. Not a bad company, just not firing on all cylinders — and there are brighter spots out there for your money.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/a247dd4db1a65abc